MediView XR, a medical technology (medtech) company, has received clearance from the US Food and Drug Administration (FDA) for its augmented reality (AR) surgical navigation system, XR90. This platform allows healthcare providers to visualize and navigate a patient’s internal soft tissues, vascular, organ, and skeletal structures in 3D using CT images. The system also combines CT imaging with ultrasound to display 3D holographic images beneath the patient’s skin, enabling minimally invasive procedures like tumor ablations and biopsies. The XR90 system utilizes a Holographic Light Ray to track and display the path of a physician’s instrument for surgical navigation.
This clearance from the FDA comes on the heels of MediView XR securing $15 million in strategic funding, with a previous investment of $9.9 million. The company has also entered into a know-how agreement with the renowned Mayo Clinic, which will provide technology, clinical expertise, and research support to accelerate innovation and advance augmented reality solutions for medical procedures. Additionally, MediView XR has collaborated with GE Healthcare to develop the OmnifyXR Interventional Suite System, which integrates GE’s imaging technologies with MediView’s augmented reality and surgical navigation expertise. This system will enable physicians to evaluate multiple live imaging displays in 3D holographic form.
MediView XR is not the only company in the medtech industry to offer surgical navigation platforms utilizing extended reality. Augmedics recently raised $82.5 million in Series D financing, while Osso VR secured $66 million in Series C funding in 2022 and $27 million in Series B funding in 2021. These companies are capitalizing on the growing demand for innovative solutions in surgical navigation and are making significant strides in the field of extended reality.
The use of augmented reality in surgical navigation has the potential to revolutionize medical procedures by providing healthcare providers with real-time, accurate, and detailed anatomical information. By overlaying holographic images onto a patient’s body, physicians can gain a deeper understanding of the internal structures and make more informed decisions during surgeries. This technology also enables minimally invasive procedures, reducing patient discomfort and recovery time.
The collaboration between Mediview XR and Mayo Clinic highlights the importance of partnerships between technology companies and healthcare institutions in driving innovation in the medical field. By combining expertise in technology, clinical practice, and research, these collaborations can accelerate the development and adoption of cutting-edge solutions that benefit patients and healthcare providers alike.
The recent investment and funding secured by Mediview XR, Augmedics, and Osso VR demonstrate the growing interest and support for augmented reality solutions in the medical industry. As the demand for advanced surgical navigation systems continues to rise, these companies are well-positioned to capitalize on the market opportunities and shape the future of healthcare.
In conclusion, Mediview XR’s FDA clearance for its AR surgical navigation system, XR90, marks a significant milestone in the company’s journey to revolutionize medical procedures. The integration of augmented reality into surgical navigation allows healthcare providers to visualize a patient’s internal structures in 3D and perform minimally invasive procedures with precision. With strategic funding, collaborations with renowned institutions, and the support of other players in the industry, Mediview XR is poised to make a lasting impact in the field of extended reality in healthcare.
